Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free LLY Stock Alerts

Eli Lilly and Company (LLY) Competitors

Eli Lilly and Company logo
$1,147.06 -2.30 (-0.20%)
As of 09/4/2026 03:58 PM Eastern
Compare

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

Should you buy Eli Lilly and Company stock or one of its competitors? Eli Lilly and Company's main competitors and comparable companies include Amgen (AMGN), Biogen (BIIB), Incyte (INCY), NVIDIA (NVDA), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size.

How does Eli Lilly and Company compare to Amgen?

Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B16.57$20.64B$29.8038.49
Amgen$38.10B6.21$7.71B$16.0927.17

Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Eli Lilly and Company pays out 23.2% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has raised its dividend for 11 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Eli Lilly and Company has a net margin of 33.53% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Eli Lilly and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company33.53% 97.83% 23.23%
Amgen 22.95%124.14%13.18%

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eli Lilly and Company has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Eli Lilly and Company presently has a consensus price target of $1,292.18, suggesting a potential upside of 12.65%. Amgen has a consensus price target of $381.68, suggesting a potential downside of 12.71%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, equities research analysts clearly believe Eli Lilly and Company is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83
Amgen
3 Sell rating(s)
13 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.40

In the previous week, Eli Lilly and Company had 105 more articles in the media than Amgen. MarketBeat recorded 142 mentions for Eli Lilly and Company and 37 mentions for Amgen. Eli Lilly and Company's average media sentiment score of 1.14 beat Amgen's score of 0.53 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
106 Very Positive mention(s)
15 Positive mention(s)
16 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
Amgen
24 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Eli Lilly and Company beats Amgen on 15 of the 19 factors compared between the two stocks.

How does Eli Lilly and Company compare to Biogen?

Eli Lilly and Company (NYSE:LLY) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Eli Lilly and Company has higher revenue and earnings than Biogen. Eli Lilly and Company is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B16.57$20.64B$29.8038.49
Biogen$10.03B3.25$1.29B$5.6539.08

Eli Lilly and Company has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Eli Lilly and Company presently has a consensus price target of $1,292.18, indicating a potential upside of 12.65%. Biogen has a consensus price target of $228.50, indicating a potential upside of 3.47%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, equities research analysts plainly believe Eli Lilly and Company is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83
Biogen
1 Sell rating(s)
13 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
2.58

Eli Lilly and Company has a net margin of 33.53% compared to Biogen's net margin of 8.32%. Eli Lilly and Company's return on equity of 97.83% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company33.53% 97.83% 23.23%
Biogen 8.32%11.18%6.88%

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Eli Lilly and Company had 111 more articles in the media than Biogen. MarketBeat recorded 142 mentions for Eli Lilly and Company and 31 mentions for Biogen. Eli Lilly and Company's average media sentiment score of 1.14 beat Biogen's score of 1.05 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
106 Very Positive mention(s)
15 Positive mention(s)
16 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
18 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Eli Lilly and Company beats Biogen on 13 of the 16 factors compared between the two stocks.

How does Eli Lilly and Company compare to Incyte?

Incyte (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Eli Lilly and Company has a net margin of 33.53% compared to Incyte's net margin of 27.71%. Eli Lilly and Company's return on equity of 97.83% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Incyte27.71% 29.93% 22.88%
Eli Lilly and Company 33.53%97.83%23.23%

97.0% of Incyte shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Incyte currently has a consensus price target of $124.05, indicating a potential downside of 2.13%. Eli Lilly and Company has a consensus price target of $1,292.18, indicating a potential upside of 12.65%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte
0 Sell rating(s)
12 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.54
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83

Eli Lilly and Company has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$5.14B5.00$1.29B$7.8516.15
Eli Lilly and Company$65.18B16.57$20.64B$29.8038.49

In the previous week, Eli Lilly and Company had 129 more articles in the media than Incyte. MarketBeat recorded 142 mentions for Eli Lilly and Company and 13 mentions for Incyte. Incyte's average media sentiment score of 1.28 beat Eli Lilly and Company's score of 1.14 indicating that Incyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Incyte
11 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eli Lilly and Company
106 Very Positive mention(s)
15 Positive mention(s)
16 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Eli Lilly and Company beats Incyte on 12 of the 16 factors compared between the two stocks.

How does Eli Lilly and Company compare to NVIDIA?

Eli Lilly and Company (NYSE:LLY) and NVIDIA (NASDAQ:NVDA) are related large-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Eli Lilly and Company has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, NVIDIA has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market.

In the previous week, NVIDIA had 241 more articles in the media than Eli Lilly and Company. MarketBeat recorded 383 mentions for NVIDIA and 142 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 1.14 beat NVIDIA's score of 0.81 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
106 Very Positive mention(s)
15 Positive mention(s)
16 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
NVIDIA
211 Very Positive mention(s)
52 Positive mention(s)
67 Neutral mention(s)
44 Negative mention(s)
4 Very Negative mention(s)
Positive

Eli Lilly and Company presently has a consensus price target of $1,292.18, indicating a potential upside of 12.65%. NVIDIA has a consensus price target of $324.83, indicating a potential upside of 41.01%. Given NVIDIA's stronger consensus rating and higher probable upside, analysts plainly believe NVIDIA is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83
NVIDIA
0 Sell rating(s)
3 Hold rating(s)
50 Buy rating(s)
2 Strong Buy rating(s)
2.98

Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. NVIDIA pays an annual dividend of $1.00 per share and has a dividend yield of 0.4%. Eli Lilly and Company pays out 23.2% of its earnings in the form of a dividend. NVIDIA pays out 12.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has increased its dividend for 11 consecutive years and NVIDIA has increased its dividend for 1 consecutive years. Eli Lilly and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

NVIDIA has a net margin of 63.66% compared to Eli Lilly and Company's net margin of 33.53%. Eli Lilly and Company's return on equity of 97.83% beat NVIDIA's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company33.53% 97.83% 23.23%
NVIDIA 63.66%96.04%71.00%

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 65.3% of NVIDIA shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by company insiders. Comparatively, 3.9% of NVIDIA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NVIDIA has higher revenue and earnings than Eli Lilly and Company. NVIDIA is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B16.57$20.64B$29.8038.49
NVIDIA$215.94B25.71$120.07B$7.9129.12

Summary

NVIDIA beats Eli Lilly and Company on 13 of the 20 factors compared between the two stocks.

How does Eli Lilly and Company compare to Viking Therapeutics?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Eli Lilly and Company has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Eli Lilly and Company presently has a consensus price target of $1,292.18, indicating a potential upside of 12.65%. Viking Therapeutics has a consensus price target of $96.63, indicating a potential upside of 177.10%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.83
Viking Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75

Eli Lilly and Company has a net margin of 33.53% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 97.83% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company33.53% 97.83% 23.23%
Viking Therapeutics N/A -94.56%-82.75%

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B16.57$20.64B$29.8038.49
Viking TherapeuticsN/AN/A-$359.64M-$4.66N/A

In the previous week, Eli Lilly and Company had 128 more articles in the media than Viking Therapeutics. MarketBeat recorded 142 mentions for Eli Lilly and Company and 14 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.14 beat Viking Therapeutics' score of 0.92 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
106 Very Positive mention(s)
15 Positive mention(s)
16 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
Viking Therapeutics
10 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Eli Lilly and Company News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLY vs. The Competition

Export
MetricEli Lilly and CompanyPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$1.08T$12.19B$7.21B$23.59B
Dividend Yield0.60%2.59%2.54%3.73%
P/E Ratio38.49792.20273.8429.33
Price / Sales16.57760.84625.5519.82
Price / Cash45.7215.1828.9219.95
Price / Book40.8611.0911.014.83
Net Income$20.64B$2.83B$3.49B$1.07B
7 Day Performance-1.16%4.42%1.63%0.43%
1 Month Performance-3.34%6.88%4.42%-0.78%
1 Year Performance57.92%10.00%24.21%12.82%

Eli Lilly and Company Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLY
Eli Lilly and Company
4.9458 of 5 stars		$1,147.06
-0.2%		$1,292.18
+12.7%		+57.9%$1.08T$65.18B38.4950,000
AMGN
Amgen
4.024 of 5 stars		$432.42
-1.0%		$380.43
-12.0%		+54.1%$233.78B$36.75B26.8831,500
BIIB
Biogen
3.5042 of 5 stars		$218.50
-1.4%		$227.79
+4.2%		+57.0%$32.28B$9.89B38.677,500
INCY
Incyte
3.6413 of 5 stars		$124.37
-2.6%		$123.10
-1.0%		+46.3%$25.21B$5.14B15.842,844
NVDA
NVIDIA
4.9136 of 5 stars		$217.55
-4.6%		$322.61
+48.3%		+37.9%$5.24T$215.94B27.5042,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:LLY) was last updated on 9/7/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel